1.Clinical characteristics of acute drug-induced dystonia in pediatric patients.
Hyun Woong PARK ; Jae Ryung KWAK ; Ji Sook LEE
Clinical and Experimental Emergency Medicine 2017;4(3):133-137
OBJECTIVE: Dystonia is a movement disorder in which muscles contract uncontrollably. Acute drug-induced dystonia (DID) can be diagnosed through detailed history taking and physical examination. This study aimed to identify the clinical characteristics of DID in children, which could help emergency physicians diagnose these conditions more efficiently. METHODS: We reviewed medical records of children aged below 18 years diagnosed with drug-related dystonia after discharge from the emergency department over 10 years. We collected the patients’ age, sex, suspected causative drugs, initial diagnosis of the prescribing physician, duration of drug-taking, diagnostic evaluations, treatment methods, and prognosis. RESULTS: Seventy-nine patients were enrolled. The mean age was 11.3±4.9 years (range, 4.0 months to 18.0 years), and 41 patients (51.9%) were boys. The most common cause of DID was gastrointestinal medications in 45 patients (57.0%), followed by antipsychotics in 23 patients (29.1%). Eleven (24.4%) out of 45 patients with DID due to gastrointestinal medications had the initial diagnosis of upper respiratory infection, and seven (30.4%) out of 23 patients with DID due to antipsychotics had the initial diagnosis of non-psychotic diseases. Younger children received more diagnostic procedures and were more frequently admitted. A benzodiazepine (67.1%) was the most common single drug for treatment. CONCLUSION: Physicians should not only acknowledge DID in order to reduce unnecessary workup and admission, but also know that antiemetics and antipsychotics are common causes of DID. Therefore, physicians should try to avoid multidrug prescriptions in children.
Antiemetics
;
Antipsychotic Agents
;
Benzodiazepines
;
Child
;
Diagnosis
;
Dystonia*
;
Emergencies
;
Emergency Service, Hospital
;
Humans
;
Medical Records
;
Movement Disorders
;
Muscles
;
Pharmaceutical Preparations
;
Physical Examination
;
Prescriptions
;
Prognosis
2.The Efficacy of Photodynamic Therapy With Verteporfin for Polypoidal Choroidal Vasculopathy: Retrospective Multi-Center Case Study.
Jae Pil SHIN ; Hyoung Jun KOH ; Oh Woong KWON ; Si Yeol KIM ; Ha Kyoung KIM ; Dong Heun NAM ; Woo Ho NAM ; Kyu Hyung PARK ; Boo Sup OUM ; Jae Ryung OH ; Seung Young YU ; Ill Han YOON ; Hee Sung YOON ; Sung Chul LEE ; Eun Goo LEE ; Jae Heung LEE ; Jeong Hee LEE ; In Young CHUNG ; Hee Seung CHIN ; Kuhl HUH ; Hyung Woo KWAK
Journal of the Korean Ophthalmological Society 2009;50(3):365-375
PURPOSE: To evaluate the efficacy of photodynamic therapy (PDT) with verteporfin for polypoidal choroidal vasculopathy (PCV) in Korean patients. METHODS: Clinical data of patients who were treated with PDT for PCV and followed up for more than 6 months were collected from 14 hospitals around the country. The changes in the best corrected visual acuity, angiographic outcome, retinal thickness measured by optical coherence tomography (OCT), and adverse effects of treatment were evaluated. RESULTS: Eighty six patients (86 eyes) were recruited (male: 75.6%, age: 65.9+/-8.3 years, mean follow-up: 14.8+/-10.2 months). The mean logMAR visual acuity at baseline was 0.55+/-0.32 and did not show any statistically significant difference from the final mean logMAR visual acuity (0.53+/-0.54) (p=0.639). The mean treatment session number of PDT was 2+/-1.2. Visual acuity stabilized or improved in 70.9% of patients. Visual acuity improved by more than 2 lines in 33 eyes (38.4%) and worsened by more than 2 lines in 21 eyes (24.4%) of patients. Vascular leakage decreased in 62.5% of patients in fluorescein angiography and polypoidal lesions disappeared or were reduced in 57.3% of patients in indocyanine green angiography. There was no systemic adverse effect of PDT, but increased subretinal hemorrhage after PDT occurred in 10 eyes (11.6%). CONCLUSIONS: In polypoidal choroidal vasculopathy, photodynamic therapy with verteporfin is safe and effective for preserving visual acuity and reducing vascular leakage and retinal thickness.
Angiography
;
Choroid
;
Eye
;
Fluorescein Angiography
;
Hemorrhage
;
Humans
;
Indocyanine Green
;
Photochemotherapy
;
Porphyrins
;
Retinaldehyde
;
Retrospective Studies
;
Tomography, Optical Coherence
;
Triazenes
;
Visual Acuity
3.Photodynamic Therapy for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.
Hyeong Gon YU ; Se Woong KANG ; Woo Ho NAM ; Hyoung Jun KOH ; Hyung Woo KWAK ; Oh Woong KWON ; Si Yeol KIM ; In Taek KIM ; Ha Kyoung KIM ; Hyun Woong KIM ; Young Jung ROH ; Jun Woong MOON ; Kyu Hyung PARK ; Suk Ho BYEON ; Su Jeong SONG ; Jae Kyoun AHN ; Boo Sup OUM ; Jae Ryung OH ; Seung Young YU ; Ill Han YOON ; Sung Chul LEE ; Won Ki LEE ; Jae Heung LEE ; Jeong Hee LEE ; Ji Eun LEE ; Tae Gon LEE ; Gwang Ju CHOI ; Don Il HAM ; Kuhl HUH ; Hum CHUNG
Journal of the Korean Ophthalmological Society 2007;48(6):789-798
PURPOSE: To investigate the effects of repeated photodynamic therapy (PDT) for subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD) in Korean patients. METHODS: Clinical data of patients who were treated with repeated (3 times or more) PDT for subfoveal choroidal neovascularization secondary to AMD and followed up for more than 6 months were collected from 17 hospitals around the country. Visual outcomes at 12 and 24 months, follow-up were compared between subtypes of choroidal neovascularization. The factors related to final visual prognosis and PDT-related adverse effects were evaluated. RESULTS: 244 patients (244 eyes) were recruited (male: 60%, age: 67.7+/-9.1 years). The portion of patients with predominantly classic, minimally classic, and occult without classic choroidal neovascularization was 57%, 13%, and 24%, respectively and that of patients with visual improvements or less than moderate visual loss at 24 months follow-up were 28%, 38%, 30% and 47%, 56%, and 65%, respectively. Baseline visual acuity and age were significantly related to the final visual prognosis (p<0.05). PDT-related adverse events developed in 15 (6.1%) patients, but most were mild and transient. CONCLUSIONS: Repeated PDT for subfoveal choroidal neovascularization secondary to AMD has effects comparable to those of previous prospective, controlled trials without any significant safety concerns in Korea.
Choroid*
;
Choroidal Neovascularization*
;
Follow-Up Studies
;
Humans
;
Korea
;
Macular Degeneration*
;
Photochemotherapy*
;
Prognosis
;
Visual Acuity